A rapidly evolving pipeline worth monitoring daily
Alzheimer's disease represents one of the largest unmet medical needs in neurology, and the clinical trial pipeline reflects it. Following lecanemab and donanemab, the amyloid-targeting approach has validated a therapeutic direction and opened the door for second-generation programs, combination strategies, and earlier-stage prevention trials. Meanwhile, tau-targeting programs, synaptic protection, neuroinflammation, and lifestyle/prevention approaches are all active areas.
The Alzheimer's trial landscape spans a wide spectrum, from small mechanistic pilot studies to large prevention trials enrolling thousands of cognitively normal participants. Professionals monitoring this pipeline need to distinguish breakthrough signals (a new Phase 3 anti-tau study, a novel combination with approved anti-amyloid therapies) from lower-signal noise (observational registries, small biomarker studies).
Key signals that Alzheimer's professionals track:
- New amyloid-targeting Phase 2/3 programs, second-generation anti-amyloid antibodies and small molecules
- Tau-targeting programs advancing into Phase 2 proof-of-concept and Phase 3 pivotal studies
- Neuroinflammation and TREM2/microglial pathway programs entering clinical stages
- Synaptic and neuroprotection approaches, downstream targets beyond amyloid and tau
- Prevention trials: studies in pre-symptomatic and MCI populations using biomarker enrichment
- Biomarker and diagnostics studies that shape trial design for the next generation of programs
- Combination therapy trials combining approved anti-amyloid agents with new mechanisms
Get daily Alzheimer's trial digest
Set your profile once. Receive a filtered daily digest of new and updated Alzheimer's trials. Free plan, no credit card required.
Get the Free DigestA primary completion date pushed out, enrollment cut, or a primary endpoint changed in the last 90 days. Active trials only.
| Trial | Warning signs | Status |
|---|---|---|
| A Nutritional and Pharmacological Intervention for Body, Brain, and Longevity… NCT06682767 | Primary completion moved at least 11 months later Primary endpoint reworded | Not Yet Recruiting |
70 more on the Trials at Risk page. See which trials →
Phase 2 and Phase 3 trials with a primary completion date in the next 180 days, as ClinicalTrials.gov estimates it today. Active trials only.
| Trial | Scheduled | Phase |
|---|---|---|
| Effect of Equol Supplementation on Arterial Stiffness and Cognition in Healthy… NCT05741060 | Oct 31, 2026 · Estimated | Phase 2 |
34 more on the Completions page. See the calendar →
What DataLookout monitors for Alzheimer's disease
Configure your profile with condition and mechanism keywords to match your specific intelligence needs:
- Condition keywords: "Alzheimer's disease", "Alzheimer disease", "dementia", "mild cognitive impairment", "MCI", "vascular dementia", "Lewy body dementia"
- Mechanism keywords: "amyloid", "beta-amyloid", "tau", "TREM2", "neuroinflammation", "synaptic", "cholinesterase"
- Target-specific: "BACE inhibitor", "gamma secretase", "anti-amyloid antibody", "anti-tau", "GLP-1" (emerging prevention evidence)
- Phase filter: Phase 2/3 for commercial intelligence, or all phases including early Phase 1 mechanism exploration
- Sponsor filter: Industry-sponsored programs for BD and competitive tracking, all sponsors for full pipeline coverage
What DataLookout adds to ClinicalTrials.gov
ClinicalTrials.gov RSS feeds tell you that a study record was updated. DataLookout compares each record against the previous day across 13 tracked fields and tells you which one changed, with the old and new values, for every Alzheimer's Disease trial on your watchlist. Each change is marked Stopped, Notable or Minor, so a trial being terminated does not read the same as a few sites being added.
Who uses Alzheimer's trial monitoring
CNS pharma BD and portfolio strategy teams
BD teams at neurology-focused pharmaceutical companies track the Alzheimer's pipeline to identify licensing opportunities, evaluate competitive threats to existing or planned programs, and inform pipeline investment decisions. With multiple Phase 3 anti-amyloid antibodies having now reported, the strategic question has shifted to combinations, earlier intervention, and non-amyloid approaches, all areas generating new trial registrations continuously.
Neurology biotech analysts and investors
Investors covering CNS use trial registrations as leading indicators of pipeline maturation. A new Phase 3 anti-tau program or a prevention trial launching with biomarker enrichment can signal the strategic direction of the field 3–5 years before pivotal readouts. Daily trial monitoring ensures no pipeline development is missed.
Academic research groups and clinical sites
University medical centers and Alzheimer's research networks track new trial registrations to identify collaboration opportunities, understand competitive enrollment dynamics, and position their sites for participation in upcoming pivotal studies.
Alzheimer's patient advocacy organizations
Organizations like the Alzheimer's Association and Alzheimer's Research Foundation use clinical trial awareness to connect patients and families with appropriate study opportunities, particularly important for early-stage prevention trials that require participants with specific biomarker profiles.
Frequently asked questions
How current is the Alzheimer's trial data?
Our pipeline fetches from ClinicalTrials.gov every morning. Studies posted or updated in the preceding 24 hours appear in that day's digest. ClinicalTrials.gov is updated as sponsors register new trials or submit protocol amendments, typically within 24–48 hours.
Can I monitor amyloid and tau programs separately?
Yes. On Pro ($49/month, or $490/year), you can save up to 10 searches, for example, one tracking anti-amyloid programs and another monitoring tau-targeting and neuroinflammation programs, each delivering a focused daily digest.
Does DataLookout cover Alzheimer's prevention trials?
Yes. Prevention and pre-symptomatic trials registered on ClinicalTrials.gov are included. Adding keywords like "prevention", "pre-clinical Alzheimer's", "cognitively normal", or "amyloid-positive" to your profile will surface studies targeting prevention in high-risk or biomarker-positive populations.
Does DataLookout cover Lewy body dementia and frontotemporal dementia?
Yes, you can include keywords for Lewy body dementia, frontotemporal dementia (FTD), progressive supranuclear palsy (PSP), and other neurodegenerative conditions alongside or separate from Alzheimer's-specific terms.
976 active trials, 567 recruiting.
Industry sponsors run 201 of these trials. The rest are run by universities, hospitals, government bodies and other non-commercial sponsors. The table below lists the 5 largest of 126.
| Top industry sponsor | Active trials |
|---|---|
| Eli Lilly and Company | 19 |
| Biogen | 13 |
| Bristol-Myers Squibb | 9 |
| Roche / Genentech | 8 |
| Karuna Therapeutics | 4 |
| Trial | Status | Latest tracked change | Seen |
|---|---|---|---|
| Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's… NCT03019757 | Recruiting | Study completion pushed from Dec 2026 to Dec 31, 2027 | 2026-10-16 |
| A Study of Donanemab (LY3002813) in Participants With Early Symptomatic… NCT07838155 | Not Yet Recruiting | Start date pushed from Oct 2026 to Nov 2026 | 2026-10-16 |
| CMN LIFU for Enhanced Glymphatic Clearance in Amyloid-Positive MCI NCT07866768 | Recruiting | Start date pushed from Sep 2026 to Oct 2026 | 2026-10-15 |
| Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the… NCT05531526 | Active, Not Recruiting | Study completion moved earlier from Dec 2027 to Oct 2027 | 2026-10-15 |
| Digital Lifestyle Coaching for Alzheimer's Disease Prevention in APOE4 Carriers NCT07646054 | Enrolling by Invitation | Primary completion pushed from Jul 31, 2028 to Aug 31, 2028 | 2026-10-15 |
Each trial page shows every change DataLookout has recorded for that trial.
DataLookout checks ClinicalTrials.gov every day and records what changed on each trial: status, enrollment, phase, primary endpoint, completion dates, sites, sponsor, and the stated reason a trial stopped. Add a sponsor or a disease to your watchlist, or save any search, and the changes arrive in a daily or weekly email digest.
Free, $0 forever: 1 sponsor + 1 disease watchlist, 1 saved search in your email digest, track up to 5 individual trials, daily change detection, Trials at Risk (top 2 trials), the weekly report (top 3 trials). No credit card.
Pro, $49/month or $490/year: 10 sponsor + 10 disease watchlists, 10 saved searches in your email digest, track up to 25 individual trials, full Trials at Risk list, Completions calendar, the full weekly report, landscape reports, CSV export.